MI-MMS-HOLDINGS
17.7.2024 12:06:28 CEST | Business Wire | Press release
MMS, a data-focused clinical research organization (CRO), announced today that Ben Dudley has been appointed as the company’s new Chief Commercial Officer (CCO). Based in the UK, Ben Dudley brings more than 25 years of life sciences expertise on the CRO and Sponsor side, holding previous operational and commercial leadership roles at Parexel, Covance, and AstraZeneca.
As CCO at MMS, Ben will focus on:
- Strategic growth planning, working closely with other members of the Executive Leadership Team (ELT) to refine the vision, strategy, and goals for continued growth and expansion of MMS globally.
- Commercial leadership, understanding sponsor needs and guiding customer relationship management across global accounts; and
- Marketing strategy, overseeing campaigns that showcase the value-add of MMS service offerings, which will impact our customer successes as well as have a positive impact on patient health.
“We were deliberate in our choice of a CCO who brings scientific strength, agility, and leadership to help continue to move MMS forward, and Ben’s experience is a great fit,” said Dr. Uma Sharma, CEO of MMS. “Ben’s passion for our industry, his commercial expertise, and proven leadership give us added momentum to drive our strategic vision, foster key partnerships, and significantly enhance our market presence.”
Data excellence is the need of the hour and what MMS brings to the industry.
"I am thrilled to join MMS at such an exciting time in the company's evolution," said Ben Dudley. "The company holds a significant place in the global CRO landscape, and I have witnessed the strength of their expertise over the years. I relish the opportunity to be part of the leadership of an organization with unique capabilities and culture as we continue the next stage of growth and delivery for our customers.”
This year, MMS celebrates 18 years globally, recently being named a Great Place to Work in all major regions of the world. MMS is known globally for data-focused CRO services, including:
- Bundled Biometrics solutions, starting with the IND, effectively managing all data collection, analysis, and integrating non-traditional data and submission analyses.
- Regulatory submissions, beginning with global regulatory strategy for multiple markets followed by execution of successful marketing applications (data, writing, and publishing/submission) with a flawless track record and industry leadership with over 50 submissions completed in the past five years.
- Other key areas, including Regulatory and Medical Writing from IND to Phase 3, Quality and Compliance (complete GxP globally), Drug Safety and Pharmacovigilance, Clinical Trial Transparency, and more.
View the entire MMS Executive Leadership Team (ELT) at https://www.mmsholdings.com/executive-leadership/
About MMS
MMS Holdings (MMS) is an award-winning, data-focused clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, an 18-year track record, AI technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner. With a global footprint across four continents, MMS maintains an industry-leading customer satisfaction rating.
For more information, visit www.mmsholdings.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717384423/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Coulson Aviation Introduces CFR HALO, a Long-Term Fire Retardant Engineered for Modern Aerial Firefighting30.7.2026 08:03:00 CEST | Press release
First Coulson EmberWorks product is undergoing qualification in France and evaluation for inclusion on the USDA Forest Service Qualified Products List Coulson Aviation today introduced CFR HALO, a next-generation long-term fire retardant engineered specifically for modern aircraft, tank systems, and wildfire missions. It is the first product from Coulson EmberWorks, the company’s research and development division dedicated to advancing aerial firefighting technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729960073/en/ Coulson Aviation has introduced CFR HALO, a next-generation long-term fire retardant engineered specifically for modern aircraft, tank systems and wildfire missions. It is designed with mission-optimized viscosity and flow characteristics to improve drop cohesion, reduce airborne drift, and support more accurate placement within the intended target area. CFR HALO is currently advancing through ind
SES Reports H1 2026 Results & Reiterates Full-Year Outlook30.7.2026 07:30:00 CEST | Press release
SES S.A. announces financial results for the three and six months ended June 30, 2026. H1 2026 Performance (€ million) H1 2026 as reported (1) H1 2025 as reported (1) ∆ At constant FX (2) H1 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.17 1.08 1.08 Revenue 1,602 978 +72.4% 1,799 -5.0% Adjusted EBITDA (4) 725 521 +47.0% 824 -6.2% 1) ‘Reported basis’ with Intelsat fully consolidated from July 17, 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralize currency variations 3) ‘Like-for-like basis’ is as if Intelsat was fully consolidated from January 1, 2024 4) Excluding operating expenses/income recognized in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) Networks revenue up +89.0% yoy(1) supported by growth in Mobility (+169.9% yoy(1); including positive impact from a contract restructuring in
AB InBev Reports Second Quarter 2026 Results30.7.2026 07:02:00 CEST | Press release
Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729033132/en/ Regulated information1 “Cheers to beer – our performance this quarter reflects the strength of the beer category and the consistent execution of our strategy. Through investment in our megabrands and mega platforms, innovation and offering more choices across more occasions, we are strengthening the cultural relevance of our brands with consumers. Thank you to our colleagues for their commitment and disciplined execution, which position us well to continue our momentum.” – Michel Doukeris, CEO, AB InBev Revenue +5.6% Revenue increased by 5.6% in 2Q26 with revenue per hl growth of 4.2% and by 5.7% in HY26 with revenue per hl growth of 4.3%. Reported revenue increased by 11.0%
Kioxia Commences Sample Shipments of 9th-Generation BiCS FLASH™ 1Tb TLC Devices30.7.2026 07:00:00 CEST | Press release
The New Devices Incorporate Existing Memory Cell and Advanced CMOS Technologies to Achieve High Investment Efficiency Kioxia Corporation, a world leader in memory solutions, today announced it has commenced sample shipments of 1Tb (terabit) Triple-Level Cell (TLC) memory devices incorporating its 9th-generation BiCS FLASH™ 3D flash memory technology1. The devices are designed to support applications such as AI-enabled PCs and smartphones with low- to mid-level storage capacities that require high performance. Kioxia continues to pursue a dual-axis strategy based on its innovative CMOS directly Bonded to Array (CBA) technology2 and On-Pitch Select Gate Drain (OPS) technology3. Under its unique dual-axis strategy, Kioxia is simultaneously advancing two distinct product lines: its 9th-generation solutions, which deliver high performance at relatively low cost of investing, and its 10th-generation technology, which leverages advanced layer stacking to achieve massive capacity and superior
Cessna Citation CJ3 Gen3 Achieves First Flight, Advancing Next-Generation Light Jet Toward Certification29.7.2026 18:31:00 CEST | Press release
All three Citation Gen3 light jets are now in flight testing, bringing Garmin Emergency Autoland and customer-inspired enhancements to the next generation of business aviation. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently achieved a key milestone as the Cessna Citation CJ3 Gen3 prototype aircraft completed its first flight, advancing the next-generation light jet toward certification. With this milestone, all three next-generation Citation light jets — the CJ4 Gen3, CJ3 Gen3 and M2 Gen3 — have entered flight testing, demonstrating continued momentum across the Cessna next-generation light jet portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729333762/en/ Cessna Citation CJ3 Gen3 achieves first flight, advancing next-generation light jet toward certification. (Photo credit: Textron Aviation) “This achievement continues the forward momentum of the CJ3 Gen3 program and reflects the discipline,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom